Immunai, a startup developing AI to predict immune system response, has received USD 20 million in financing from investors like Viola Ventures and TLV Partners to develop a new technology to map the immune system of any patient. The company will use all of the funding for the development of its tech and business functions while hiring new scientists, engineers, and machine learning experts. Immunai claims that the funding it has received is going to be a big push in increasing its already strong analysis and growth actions.
Immunai was founded by Noam Solomon, a Harvard and MIT-educated postdoctoral researcher, and former Palantir engineer, Luis Voloch in collaboration with Ansuman Satpathy, a professor of cancer immunology at Stanford University, and Danny Wells, a data scientist at the Parker Institute for Cancer Immunotherapy.
The two founders Noam Solomon and Luis Voloch with a deep interest in computational biology and systems engineering, after getting touch with the other two, formulated the goals of the biotech company.
Solomon stated that four of them together deliver the understanding of all of the know-how and study material to be further introduced into the work and Ansuman and Danny to deliver the single-cell biology.
For the past two years, Immunai’s founding team has been working cautiously to develop a new technology to map the immune system of a patient. Immunai said in a statement, “The team has already published work on the origin of tumor-fighting T cells and PD-1 blockade.”
Studies say that cell therapies and cancer immune therapies are responsible for changing the methods in the medicine world and are even offering new treatments for conditions. The immune system is very complex and therapy developers have few insights into how treatments will affect the immune system. The diversity of individual product variation can considerably change the way a patient will respond to the treatment.
Danny Wells told that media that they have already implemented a complicated engineering pipeline. He said, “We wanted to scale to hundreds of patients and thousands of samples. Right now, in the world of cancer therapy, new drugs are entering the market and are called checkpoint inhibitors. We are also trying to understand how these molecules work and find out new combinations and new targets. We need to see the immune system in full granularity.”
“Immunai allows researchers to do carry out studies. It’s a vertically integrated platform for single-cell profiling. We go even further to figure out what the biology is there and figure that out in a new combination design for the trial,” Wells added.
Immunai is studying to change the way treatments are being developed in the market by using single-cell technologies to profile cells by generating over a terabyte of data from an individual blood sample. The researchers at the company map incoming data to different human cell types and create profiles of immune responses based on different elements of the cells.
Immunai claims to already be in clinical partnerships with over ten medical centers and several biopharma companies.